When Daniel Haders, Ph.D., was working in venture capital, he was on the hunt for an AI-driven drug discovery company that ...
If any proof was needed that big money is still available for AI drug development, look no further than the ten-figure series B hauled in by Isomorphic Labs. The London-based AI drug discovery firm ...
Objectives To evaluate the performance of large language models (LLMs) in risk of bias assessment and to examine whether ...
Ligand-based drug design combines AI and QSAR modeling to prioritize drug candidates, minimizing preclinical failures and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results